Efficacy and Safety of Rituximab in Treating Adult Patients with Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Prospective Study Compared with Glucocorticoids.

Drug Des Devel Ther · 2025 · PMC12667706 · PMID 41334365

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

did not reach statistical significanceno p-value reported

Descriptive data showed that treatment-naïve patients receiving RTX experienced no glucocorticoid-related adverse events, whereas relapsed patients exhibiteda statistically significant reduction in steroid dosage and a decreasing trend in relapse frequency after RTX, although the latter did not reach statistical significance.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.